发明了胰岛素的丹麦百年制药巨头诺和诺德，近年来因明星减重药司美格鲁肽的走红一度成为欧洲市值 最高的公司。但今年以来，该公司在资本市场上的"司美格鲁肽光环"褪色。上周，诺和诺德在宣布了新 CEO的任命后，公司一周股价暴跌三分之一，市值蒸发超过千亿美元。 "市场的恐慌主要由于对新任命高管的失望，加之公司下调了业绩预期，未来的发展前景不明朗。"一位 生物医药投资人对第一财经记者表示。 他是一位挑战者 在诺和诺德102年的历史上，这家胰岛素巨头只更换过5名CEO，而且全部是丹麦人。今年5月，诺和诺 德意外宣布Lars Fruergaard Jørgensen将不再担任CEO，并称将物色新人选。 Jørgensen曾一手主导了司美格鲁肽在全球的上市。在他的带领下，诺和诺德于去年6月创下接近7000亿 美元的市值新高。但由于过去一年以来，减重药全球市场环境的迅速变化，司美格鲁肽在美国市场面临 复杂的挑战，导致该公司股价从去年6月的高位已下跌超过三分之二。在这一背景下，诺和诺德做出更 替CEO的艰难决定，以安抚资本市场。 当地时间7月29日，诺和诺德公布了备受市场关注的CEO任命——一位从公司内部成长起来并不断受到 提拔的 ...

Group 1 - Novo Nordisk has appointed Maziar Mike Doustdar as the new CEO, marking the first aggressive CEO change in 60 years, following a profit warning [3] - The market reacted negatively to the announcement, with Novo Nordisk's stock price dropping nearly 30% at one point and closing down about 22%, resulting in a market value loss of over $50 billion [1][3] - Year-to-date, Novo Nordisk's stock has fallen over 44%, with its current market value approximately half of its peak last year [1][3] Group 2 - Doustdar, who has been with Novo Nordisk since 1992 and currently serves as the Vice President of International Business, will officially take over on August 7 [3] - The appointment of an internal candidate has been interpreted by the market as insufficient for the necessary transformation, with expectations for a CEO with U.S. pharmaceutical experience [3] - Doustdar acknowledged the challenges ahead, emphasizing the need for increased urgency and different execution strategies [3] Group 3 - Novo Nordisk's semaglutide, the first innovative GLP-1 weight loss drug, faces market share pressure following the approval of a competing weight loss drug by Eli Lilly [3] - The company has revised its sales growth forecast for semaglutide in the U.S. from 13%-21% down to 8%-14% for 2025 due to declining growth expectations [3] Group 4 - The U.S. is the largest and most profitable market for weight loss drugs, making it a critical battleground for Novo Nordisk and Eli Lilly, as well as for Chinese pharmaceutical companies [4] - In China, Novo Nordisk will face pressure from the expiration of semaglutide's patent in 2026, with at least ten generic versions already in late-stage clinical trials [4] Group 5 - Goldman Sachs estimated that if generics prove to be as safe and effective as Novo Nordisk's semaglutide, the drug may be forced to drop in price by about 25% in China [5] - Novo Nordisk has emphasized its commitment to innovation despite the challenges posed by generics entering the market after patent expiration [5]